EDUCATION TECHNOLOGY HEALTHCARE

WEBCAST PRESENTATION



1Q23 RESULTS

SAFE HARBOR FORWARD – LOOKING STATEMENTS

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which statements involve substantial risks and uncertainties. All statements other than statements of historical fact could be deemed forward-looking, including risks and uncertainties related to statements about our competition; our ability to attract, upsell and retain customers; our ability to increase the price of our solutions; our ability to expand our sales and marketing capabilities; general market, political, economic, COVID-19, and business conditions; and our financial targets such as revenue, share count and IFRS and non-IFRS financial measures including gross margin, operating margin, net income (loss) per diluted share, and free cash flow.

We undertake no obligation to update any forward-looking statements made in this presentation to reflect events or circumstances after the date of this presentation or to reflect new information or the occurrence of unanticipated events, except as required by law. The achievement or success of the matters covered by such forward-looking statements involves known and unknown risks, uncertainties and assumptions. If any such risks or uncertainties materialize or if any of the assumptions prove incorrect, our results could differ materially from the results expressed or implied by the forward-looking statements we make. You should not rely upon forward-looking statements as predictions of future events. Forward-looking statements represent our management's beliefs and assumptions only as of the date such statements are made. Further information on these and other factors that could affect our financial results is included in filings we make with the Securities and Exchange Commission from time to time, including the section titled "Risk Factors" in our most recent Rule 424(b) prospectus. These documents are available on the SEC Filings section of the investor relations section of our website at: <u>https://ir.afya.com.br/.</u>






- 01 STRONG PERFORMANCE
- 02 | SOLID BUSINESS EXECUTION
- **03** GROWTH WITH PROFITABILITY
- 04 FINANCIAL AND OPERATIONAL OVERVIEW









ADJUSTED NET INCOME + ADJUSTED EPS

R\$166.4MM, -0.5% YoY EPS: R\$1.77, 0.0% YoY

NET REVENUE: R\$56.7MM, +19.6% YoY



ECOSYSTEM USERS

~295k OF PHYSICIANS AND MEDICAL STUDENTS

SOLID BUSINESS EXECUTION SEGMENTS HIGHLIGHTS

UNDERGRAD

- HIGHER TICKETS IN MEDICINE COURSES IN 8.3%
- MATURATION OF MEDICAL SEATS
- BEGINNING OF CAMPUSES AND
 CONSOLIDATION OF UNIT/FITS

CONTINUING EDUCATION

- MOST SIGNIFICANT GROWTH
- ROBUST INTAKE PROCESS
- SIX NEW CAMPUSES
- COURSE MATURATION



DIGITAL SERVICES

•

 \bullet

•

RAMP-UP IN B2B ENGAGEMENT NEW CONTRACTS WITH PHARMA COMPANIES RAMP-UP IN B2B CONTRACTS




FINANCIAL AND OPERATIONAL OVERVIEW





ADJUSTED NET REVENUE – (R\$ MM)

ADJUSTED EBITDA & EBITDA MARGIN – (R\$ MM and %)




Adjusted EBITDA






ADJUSTED OPERATING CASH GENERATION & CASH CONVERSION – (R\$ MM AND %)




ADJUSTED NET INCOME & EPS – (R\$ MM)



NUMBER OF SEATS AND MEDICAL STUDENTS




MEDICAL SCHOOL NET AVERAGE TICKET – (R\$/MONTH)



Net Average Ticket Ex-Acquisitions

COMBINED TUITION FEES – (R\$ MM)




1Q22

1Q23
















TOTAL ACTIVE PAYERS – (THOUSAND)




MONTHLY ACTIVE USERS –

(THOUSAND) +13.6% 294.9 +19.6% 259.5 47.5 1Q22 1Q23 2021

Monthly Active Users represents the number of unique individuals that consumed Digital Services content in each one of our products in the last 30 days of a specific period.

NET REVENUE – (R\$ MM)









CASH AND CASH EQUIVALENTS - (R\$ MM)

NET DEBT (CASH) EXCLUDING IFRS 16 – (R\$ MM)





NET DEBT CONCILIATION (R\$ MM)





			Cost of Debt	
	Gross Debt (R\$MM)	Duration (Years)	per year	%CDI*
Loans and financing: Softbank	825	3.1	6.5%	48%
Debentures	519	4.4	15.7%	114%
Accounts payable to selling shareholders plus other financial obligations	828	1.2	13.3%	97%
Loans and financing: Others	580	1.9	15.7%	114%
Total	2,751	2.6	12.1%	89%

*Based on the annualized Interbank Certificates of Deposit ("CDI") rate for the period as a reference. 1Q23: ~13.65% p.y.



Q&A SESSION



ir.afya.com.br

Alameda Oscar Niemeyer, 119 Vila da Serra, Nova Lima | MG CEP 34006-056

ir@afya.com.br